STOCK TITAN

Rockwell Medical Inc - RMTI STOCK NEWS

Welcome to our dedicated news page for Rockwell Medical (Ticker: RMTI), a resource for investors and traders seeking the latest updates and insights on Rockwell Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Rockwell Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Rockwell Medical's position in the market.

Rhea-AI Summary
Rockwell Medical, Inc. to release Q3 2023 financial and operational results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.57%
Tags
-
Rhea-AI Summary
Rockwell Medical enters into a three-year product purchase agreement with Centers for Dialysis Care, Inc.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
-
Rhea-AI Summary
Rockwell Medical enters into a three-year product purchase agreement with Sanderling Renal Services, potentially generating millions of dollars in net sales for Rockwell Medical. Rockwell Medical will be the preferred supplier of hemodialysis concentrates to Sanderling's facilities in multiple states.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.11%
Tags
none
Rhea-AI Summary
Rockwell Medical, Inc. announces amended and restated products purchase agreement with largest customer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
none
-
Rhea-AI Summary
Rockwell Medical, Inc. to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.59%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.36%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.45%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.35%
Tags
-
Rhea-AI Summary
Rockwell Medical, Inc. has acquired the hemodialysis concentrates business from Evoqua Water Technologies for $11 million upfront in cash. The acquisition adds approximately $18 million in annual revenue and over $3.3 million in annual EBITDA for Rockwell Medical. It also expands the company's geographic footprint, customer base, and product offerings. Rockwell Medical increases its 2023 revenue guidance to between $82.0 million and $86.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.43%
Tags
Rhea-AI Summary
Rockwell Medical has entered into a three-year co-promotion services agreement with B. Braun Medical to promote its hemodialysis concentrates products to dialysis providers in the United States. B. Braun will receive a fee for any sales generated by its promotional efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
none
Rockwell Medical Inc

Nasdaq:RMTI

RMTI Rankings

RMTI Stock Data

46.94M
25.22M
3.01%
17.46%
2.3%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Wixom

About RMTI

rockwell medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (esrd) and chronic kidney disease (ckd) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. rockwell’s new innovative therapy triferic is the only fda approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. via dialysate during each dialysis treatment, triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. unlike iv iron products, triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming functional iron deficiency (fid) in esrd patients. visit www